{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:25Z","timestamp":1786119625045,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1097\/iop.0b013e318201ca26","type":"journal-article","created":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T04:38:53Z","timestamp":1296535133000},"page":"e113-e116","source":"Crossref","is-referenced-by-count":5,"title":["Cicatricial Entropion Following Docetaxel (Taxotere) Therapy"],"prefix":"10.1097","volume":"27","author":[{"given":"Altu\u011f","family":"\u00c7etinkaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Hudak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight","family":"Kulwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-36-20210129","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1634\/theoncologist.9-suppl_2-24","article-title":"Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience.","volume":"9","author":"Crown","year":"2004","journal-title":"Oncologist"},{"key":"R2-36-20210129","first-page":"1","article-title":"Single-agent docetaxel (Taxotere) in randomized phase III trials.","volume":"26","author":"Burris","year":"1999","journal-title":"Semin Oncol"},{"key":"R3-36-20210129","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S0161-6420(00)00640-0","article-title":"Canalicular stenosis secondary to docetaxel (Taxotere). A newly recognized side effect","volume":"108","author":"Esmaeli","year":"2001","journal-title":"Ophthalmology"},{"key":"R4-36-20210129","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/01.ICL.0000062464.79558.5A","article-title":"Erosive conjunctivitis and punctal stenosis secondary to docetaxel (Taxotere).","volume":"29","author":"Skolnick","year":"2003","journal-title":"Eye Contact Lens"},{"key":"R5-36-20210129","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/15569520802431369","article-title":"Acute erythema and edematous skin reaction and ectropion following docetaxel in a patient with non-small cell lung cancer.","volume":"27","author":"Kaya","year":"2008","journal-title":"Cutan Ocul Toxicol"},{"key":"R6-36-20210129","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.pcan.4500939","article-title":"Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation.","volume":"10","author":"Gupta","year":"2007","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R7-36-20210129","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0161-6420(02)00989-2","article-title":"Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer.","volume":"109","author":"Esmaeli","year":"2002","journal-title":"Ophthalmology"},{"key":"R8-36-20210129","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1200\/JCO.2005.04.4453","article-title":"Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel.","volume":"22","author":"Esmaeli","year":"2006","journal-title":"J Clin Oncol"},{"key":"R9-36-20210129","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1200\/JCO.2000.18.6.1212","article-title":"Docetaxel administered on a weekly basis for metastatic breast cancer.","volume":"18","author":"Burstein","year":"2000","journal-title":"J Clin Oncol"},{"key":"R10-36-20210129","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.IOP.0000075016.29682.E0","article-title":"Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa.","volume":"19","author":"Esmaeli","year":"2003","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R11-36-20210129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-suppl_2-3","article-title":"Preclinical pharmacology of the taxanes: implications of the differences.","volume":"9","author":"Gligorov","year":"2004","journal-title":"Oncologist"},{"key":"R12-36-20210129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00000421-200004000-00006","article-title":"Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.","volume":"23","author":"Ferraresi","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"R13-36-20210129","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/annonc\/mdf036","article-title":"Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect.","volume":"13","author":"Esmaeli","year":"2002","journal-title":"Ann Oncol"},{"key":"R14-36-20210129","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/archopht.120.9.1180","article-title":"Docetaxel secretion in tears: association with lacrimal drainage obstruction.","volume":"120","author":"Esmaeli","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R15-36-20210129","first-page":"483","article-title":"Clinical Oncology. 3rd ed.","author":"Perry","year":"2004"},{"key":"R16-36-20210129","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/07357909009012068","article-title":"Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity.","volume":"8","author":"Loprinzi","year":"1990","journal-title":"Cancer Invest"},{"key":"R17-36-20210129","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/eye.1998.83","article-title":"Sclerosing canaliculitis after 5-fluorouracil breast cancer chemotherapy.","volume":"12","author":"Lee","year":"1998","journal-title":"Eye"},{"key":"R18-36-20210129","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/01.IOP.0000066648.33513.3D","article-title":"Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil.","volume":"19","author":"Eisman","year":"2003","journal-title":"Ophthalmic Plast Recon Surg"},{"key":"R19-36-20210129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/mpo.2950030104","article-title":"Cicatricial ectropion secondary to 5-fluorouracil therapy.","volume":"3","author":"Straus","year":"1977","journal-title":"Med Pediatr Oncol"},{"key":"R20-36-20210129","first-page":"374","article-title":"Ankyloblepharon associated with systemic 5-fluorouracil treatment.","volume":"19","author":"Insler","year":"1987","journal-title":"Ann Ophthalmol"}],"container-title":["Ophthalmic Plastic & Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IOP.0b013e318201ca26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:44:57Z","timestamp":1786041897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002341-201109000-00036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/iop.0b013e318201ca26","relation":{},"ISSN":["0740-9303"],"issn-type":[{"value":"0740-9303","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}